|[December 03, 2012]
SQI Diagnostics to Extend Warrant Expiry Date
TORONTO --(Business Wire)--
SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD), a life
sciences company that develops and commercializes proprietary
technologies and products for advanced microarray diagnostics, announced
today that it has received approval from the TSX Venture Exchange to
extend the expiry of 1,199,052 outstanding common share purchase
warrants (the "Warrants") of the Company, which were issued in
connection with the Company's December 2009 private placement financing.
Each Warrant, as amended, entitles the holder thereof to purchase one
common share of the Company at any time until the close of business on
December 4, 2012 at an exercise price of $4.00 per common shares. The
Warrants will be amended, effective December 4, 2012, to extend the term
of such Warrants until December 4, 2013. All other provisions of the
Warrants will remain the same.
About SQI Diagnostics
SQI Diagnostics is a life sciences company that develops and
commercializes proprietary technologies and products for advanced
microarray diagnostics. The Company's proprietary microarray tests and
fully-automated systems are designed to simplify protein and antibody
testing workflow, increase throughput, reduce costs and provide
excellent data quality. For more information, please visit www.sqidiagnostics.com.
The contents of the Company's website are specifically not incorporated
by reference in this press release.
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "may",
"plan", "will", "estimate", "continue", "anticipate", "intend",
"expect", "believe", "in the process", "is subject to" and other similar
expressions which constitute "forward-looking information" within the
meaning of applicable securities laws. Forward-looking statements
reflect the Company's current expectation and assumptions, and are
subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including,
but not limited to, our need for additional capital to sustain our
business, general economic and market segment conditions, competitor
activity, technology changes and regulatory approvals. Such statements
reflect the current views of the Company with respect to future events
and are subject to certain risks and uncertainties and other risks
detailed from time-to-time in the Company's ongoing filings with the
securities regulatory authorities, which filings can be found at www.sedar.com.
Actual results, events, and performance may differ materially. Readers
are cautioned not to place undue reliance on these forward-looking
statements. The Company undertakes no obligation to publicly update or
revise any forward-looking statements either as a result of new
information, future events or otherwise, except as required by
applicable securities laws.
This news release does not constitute an offer to sell or a
solicitation of an offer to sell any of the securities in the United
States. The securities have not been and will not be registered under
the United States Securities Act of 1933, as amended (the "U.S.
Securities Act") or any state securities laws and may not be offered or
sold within the United States or to U.S. persons unless registered under
the U.S. Securities Act and applicable state securities laws or an
exemption from such registration is available.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
[ Back To IBM News 's Homepage ]